Biotechnology Company Announces Partnership With Healthcare Giant Johnson & Johnson
Rallybio and Johnson & Johnson Join Forces to Combat Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).
In a significant move towards advancing healthcare for the most vulnerable, Rallybio Corporation has announced a groundbreaking collaboration with healthcare giant Johnson & Johnson. This partnership is poised to usher in a new era of therapeutic approaches aimed at mitigating the risks associated with fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare but potentially life-threatening condition that affects fetuses and newborns. $Rallybio(RLYB.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment